BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 11:47:00 AM | Browse: 330 | Download: 395
Publication Name World Journal of Gastroenterology
Manuscript ID 3764
Country of Manuscript Source Italy
2013-05-21 11:07
Peer-Review Started
2013-05-21 20:12
To Make the First Decision
2013-06-24 10:27
Return for Revision
2013-07-01 13:33
2013-08-08 22:41
Second Decision
2013-08-29 07:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-29 09:52
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-01-10 14:57
Publish the Manuscript Online
2014-02-19 16:57
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib
Manuscript Source Invited Manuscript
All Author List Andrea L Inghilesi, Donatella Gallori, Lorenzo Antonuzzo, Paolo Forte, Daniela Tomcikova, Umberto Arena, Stefano Colagrande, Silvia Pradella, Bernardo Fani, Elena Gianni, Luca Boni, Giacomo Laffi, Francesco Di Costanzo and Fabio Marra
Funding Agency and Grant Number
Funding Agency Grant Number
Associazione Italiana per la Ricerca sul Cancro (AIRC)
Istituto Toscano Tumori (ITT) to Marra F
Correspondence To Fabio Marra, MD, PhD, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Largo Brambilla 3, I-50134 Florence, Italy. fabio.marra@unifi.it
Keywords Hepatocellular carcinoma; Sorafenib; Cirrhosis; Adverse events; Barcelona Clinic Liver Cancer
Core Tip The study provides information on the clinical characteristics and laboratory findings that predict survival in patients with hepatocellular carcinoma and established cirrhosis treated with sorafenib. This group of patients is particularly fragile and difficult to treat, and therapy with systemic agents, including sorafenib, requires careful monitoring. We report that parameters related to the tumor (extrahepatic spread, vascular invasion), common laboratory tests (alpha-fetoprotein or alkaline phosphatase) and patients characteristics (performance status) are significant predictors of overall survival in this group. These data provide important clinical information for the management of this type of patients.
Publish Date 2014-02-19 16:57
Citation Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
Url http://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i3.786
Full Article (PDF) WJG-20-786.pdf
Full Article (Word) WJG-20-786.doc
Revised Manuscript 3764-Review.docx
Peer-review Report 3764-Peer review(s).pdf
Answering Reviewers 3764-Answering reviewers.pdf
Scientific Editor Work List 3764-Scientific editor work list.doc
Copyright License Agreement 3754-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate 3764-Language certificate.pdf